| Revenue growth | 20.43% YoY for FY26. |
|---|---|
| Margins | EBITDA margin 20.25%; target 30-35% during expansion phase. |
| Order book | ₹800cr project value over 10 years for five PPP projects. |
| Demand visibility | Strong; fueled by PPP projects and expansion into 13 states. |
| Management confidence | High; citing aggressive expansion and maturing of existing centers. |
Growth
FY26 Revenue: ₹280.67cr (+20.43% YoY); EBITDA: ₹56.84cr (+31.02% YoY); PAT: ₹27.06cr (+22.04% YoY).
Outlook
Targeting 1,000 franchises in 24 months; adding 5 comprehensive centers and 20 labs in FY27.
Risks
One-time ₹2.92cr impact from new Labor Code; long receivable cycles in government/B2G segments.
Earnings Call filed with NSE, NSE: CHANDAN. Summary written with AI assistance from the document.
Chandan Healthcare Ltd: key numbers
- Share price
- ₹241.20
- Market cap
- ₹604.3 Cr
- Revenue (annual)
- ₹276.4 Cr
- Net profit (annual)
- ₹28.55 Cr
- P/E (TTM)
- 21.2×Sector 57.8×
- Promoter holding
- 49.61%+0.06% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chandan Healthcare Ltd
All →Chandan Healthcare Capacity Expansion
Chandan Healthcare scaled its diagnostic franchise network to 500+ centres, reaching a total of 568+ centres. It targets 1,000 centres by FY27-end and 3,000 in two years.
- diagnostic franchise collection centres
- 500 franchise centres
Chandan Healthcare Results Correction
Chandan Healthcare clarified to NSE it has one reportable segment, explaining the omission of segment-wise details in its Q4 FY27 financial results.
Chandan Healthcare Capital Structure Change
Chandan Healthcare Limited has allotted 5,99,998 equity shares upon conversion of fully convertible warrants, aggregating to ₹14.04 Crore.
- Value
- ₹14.04 Cr
Chandan Healthcare Board Meeting Outcome
Chandan Healthcare Ltd's board approved the appointment of an Independent Director, ratified cost auditor remuneration, and recommended varying the objects for utilising unutilised warrant proceeds.
Chandan Healthcare Earnings Call Transcript: Key Takeaways
Chandan Healthcare is pivoting from pharmacy trading to a high-margin diagnostic-led strategy. The company reported healthy revenue growth but is over-relying on capital-light franchise scaling to drive future profitability.
- Call
- Guides 50% growth
Chandan Healthcare Investor Presentation: Key Takeaways
Chandan Healthcare reported strong Q1 FY27 results with 19.62% YoY revenue growth and 42.27% EBITDA growth, driven by expansion into 15 states and diversified B2C, B2B, and B2G segments.